Entera Bio Reports Strong Preclinical Data for Two Oral Peptide Candidates
Summary
Entera Bio reported robust preclinical data for its EB612 (hypoparathyroidism) and EB618 (obesity) oral peptide programs at ENDO 2026. EB612 demonstrated sustained calcium increases across models, with an IND expected in late 2026, while EB618 showed dose-proportional pharmacokinetics and blood glucose effects. This positive pipeline development provides crucial scientific validation for the company's N-Tab® platform, especially following recent financial concerns including a going concern warning and subsequent capital raises. The progress is vital for a clinical-stage biotech and is co-developed with OPKO Health. An IND filing for EB612 in late 2026 is the next key milestone.
At the time of this announcement, ENTX was trading at $1.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $59.6M. The 52-week trading range was $0.91 to $3.22. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.